Johnson & Johnson Earns $1.41 in Q1 Beating Analyst Estimates

Johnson & Johnson Earns $1.41 in Q1 Beating Analyst Estimates

Johnson & Johnson Earns $1.41 in Q1 Beating Analyst Estimates



21st Century Investing with The Investment Integration Project’s William Burckart

Yarra Square Investing Greenhaven Road CapitalValueWalk's Raul Panganiban interviews William Burckart, The Investment Integration Project’s President and COO, and discuss his recent book that he co-authored, “21st Century Investing: Redirecting Financial Strategies to Drive System Change”. Q1 2021 hedge fund letters, conferences and more The following is a computer generated transcript and may contain some errors.

Johnson & Johnson (NYSE: JNJ) has just released earning reports for the first quarter of 2012. Expected earnings, according to analysts, were to be at about $1.35 per share, an increase of approximately 0.7%, but the final report came in at $1.41 up from $1.25 a year earlier.

Johnson & Johnson (NYSE: JNJ) , the age old company has seen many ups and downs over the years, but all-in-all has been a staple in every household in the country and increasingly around the world. The most recent set back comes from accusations that a subsidiary of the company, Janssen misled consumers about the safety of Risperdal, an antipsychotic medication.

An Arkansas judge ruled the company misled doctors and patients about the risks involved when using the antipsychotic medication. The jury believed Janssen deliberately used misleading marketing tactics and knowingly downplayed the possibility of developing diabetes, excessive weight gain and increased risk of stoke.

The final verdict, according to the judge and jury, was that the company lied to the public because it cared more about profits than the well-being of the people using the product. The biggest problem with the case was that no one was actually hurt. There was no proof that anyone was harmed, however the company was still forced to pay certain fines, but so far no compensation for injury has been paid.

In addition, Janssen presented ample evidence that they acted responsibly and complied fully with all laws and regulations.

But, cases like these are few and far between. In general, Johnson & Johnson (NYSE: JNJ), the multinational pharmaceutical giant has only given the best to consumers since its establishment in 1886. The company continues to develop new products, all the while never neglecting the products consumers have come to rely upon over the past 126 years. Never cutting corners and always delivering the quality consumers expect.

Very few babies in North America have grown up without Johnson & Johnson (NYSE: JNJ) baby shampoo, lotion and baby powder. These are probably the most popular products, and the ones that made the company the most famous, but the diversity of the company has continued to grow over the years. The product line now includes everything from baby care products and feminine hygiene products to orthopedic devices and internet publishing.

With the recent acquisition of Pfizer’s human healthcare department, Johnson & Johnson (NYSE: JNJ)  now has a solid hold on just about every aspect of the health and beauty industry and a growing interest in online products.

No posts to display